The Efficacy And Safety Of Hyper-CVAD/MA Regimen In The Treatment Of Relapsed Or Refractory Diffuse Large B-cell Lymphoma

Objective: To evaluate the clinical efficacy and safety of Hyper-CVAD/MA regimen in patients with relapsed or refractory diffuse large B-cell lymphoma(DLBCL).Methods: All 29 patients with relapsed or refractory DLBCL were treated with Hyper-CVAD/MA regimen after routine treatment. 21-28 days consisted of one cycle, and the therapeutic efficacy and side effects were observed after two cycles.Results: In 29 cases, the overall response rate was 44.83 %. Three patients(10.35 %) achieved a complete remission and ten(34.48 %) achieved a partial remission. The median time of the OS(overall survival) was 11 months. The one-year OS rate and two-year OS rate were 39.8 % and 29.9 %, respectively. Myelosuppression and infection were the major adverse reaction. Other side effects included gastroenteric reactions, oral mucosa inflammation, damage of live function was also observed.Conclusion: Hyper-CVAD/MA regimen can achieve a satisfied result in the treatment of relapsed or refractory DLBCL, and the toxicity was tolerable.